ITCMS is excited to announce the continuation of our annual Directors Career Symposium.
This year’s Symposium will feature speakers from the world of patient-oriented treatment, finances, and high-level research investigation at the National Cancer Institute. For the first time, this event will be held virtually and broken up into a three week series:
June 4, 2020
Lola Rahib, PhD, Director of Scientific and Clinical Affairs, Cancer Commons
Dr. Lola Rahib is the Director of Scientific and Clinical Affairs and the Lead Scientist in Pancreas Cancer at Cancer Commons. She earned her PhD in Biomedical Engineering at the University of California at Los Angeles and has worked for several biotechnology start-up companies in the Los Angeles area. Prior to Cancer Commons, she led scientific research and initiatives at the Pancreatic Cancer Action Network, including a molecular profiling program, a patient registry, and an early detection initiative. Dr. Rahib has authored many publications contributing to the field of pancreas cancer. At Cancer Commons, her roles include identifying the best-personalized options for patients and building a knowledge base to facilitate learning from each patient to rapidly optimize and expand the use of available treatments, to improve outcomes for all patients with advanced cancer.
June 11, 2020
Steven Cappell, PhD, Investigator, National Cancer Institute
Dr. Steve Cappell is Stadtman Investigator in the Laboratory of Cancer Biology and Genetics at the National Cancer Institute. Dr. Cappell received his BS from the University of Miami. He obtained his PhD from the University of North Carolina at Chapel Hill, where he studied G protein signaling in yeast in the lab of Dr. Henrik Dohlman. He completed his postdoctoral training as a Damon Runyon Cancer Research Foundation Fellow in the laboratory of Dr. Tobias Meyer at Stanford University. Dr. Cappell’s research at the NCI is focused on the regulation of the E3 ubiquitin ligase, Anaphase Promoting Complex/Cyclosome (APC/C), as a master regulator of the cell cycle.
June 18, 2020
Roman Camarda, PhD, Analyst, Aquilo Capital Management Dr. Camarda is a Research Analyst at Aquilo Capital Management, which invests in drug development companies that harness the power of cutting-edge science to address urgent medical needs. Dr. Camarda received a bachelor’s degree in Biochemistry and in Photomedia from the University of Washington, and a PhD in Biomedical Sciences from the University of California, San Francisco. Prior to joining Aquilo, he was the Lead Translational Scientist at the Buck Institute for Research on Aging. At Aquilo, Dr. Camarda’s primary role is to identify investment opportunities by interrogating the science and the business of publicly traded, human therapeutics-focused biotech companies.
The Director’s Career Symposium is organized by ITCMS and the speakers are chosen by the ITCMS Postdoctoral Fellows Committee, but the event is open to all LCCC T32 trainees. It was designed specifically to facilitate trainee career development, in particular for non-academic research career paths.
We look forward to seeing you there.